SCHEMBL5847952

SCHEMBL5847952

Cn1c(Cl)nc(-c2ccncc2)c(-c2cccc(Br)c2)c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK9 P45984 3/20 0.43
MAP4K4 O95819 2/20 0.43
CSNK1D P48730 2/20 0.43
CDC42BPA Q5VT25 2/20 0.43
MINK1 Q8N4C8 2/20 0.43
FRK P42685 1/20 0.43
CSNK1A1 P48729 1/20 0.43
MAP4K5 Q9Y4K4 1/20 0.43
MAPK1 P28482 1/20 0.42
TGFBR1 P36897 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
HIF1A Q16665 1/20 0.40
MAPK14 Q16539 5/20 0.40
MAPK13 O15264 3/20 0.40
MAPK12 P53778 2/20 0.40
GCGR P47871 2/20 0.40
MAPK11 Q15759 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5787744 0.86 CSNK1D (0.55) MAPK9MAP4K4CSNK1DCDC42BPAMINK1
SCHEMBL5849365 0.85 MAPK9 (0.43) MAPK9MAP4K4CSNK1DCDC42BPAMINK1
SCHEMBL5847695 0.83 ALDH1A1 (0.46) MAPK9MAP4K4CSNK1DCDC42BPAMINK1
SCHEMBL27507564 0.82 MAPK9 (0.49) MAPK9MAP4K4CSNK1DCDC42BPAMINK1
SCHEMBL5788934 0.82 GRIN1 (0.45) MAPK9MAP4K4CSNK1DCDC42BPAMINK1
SCHEMBL4826188 0.81 MAPK9 (0.56) MAPK9MAP4K4CSNK1DCDC42BPAMINK1
Hydrochloric Acid SCHEMBL6935269 0.81 GRIN1 (0.45) MAPK9MAP4K4CSNK1DCDC42BPAMINK1
SCHEMBL5849136 0.79 ADORA1 (0.45) MAPK9MAPK1NPC1RAB9AALDH1A1
SCHEMBL5789108 0.77 MAPK14 (0.57) CSNK1DMAPK14MAPK13MAPK12GCGR
SCHEMBL6693653 0.74 MAPK14 (0.45) CSNK1DNPC1RAB9AALDH1A1MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026326-B2 Substituted heterocyclic compounds and methods of use AMGEN INC. (US) 2006-04-11 US disclosed
US-20050038010-A1 Substituted heterocyclic compounds and methods of use AMGEN, INC. 2005-02-17 US disclosed
EP-1506186-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2005-02-16 EP disclosed
WO-2003099808-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038010-A1 Substituted heterocyclic compounds and methods of use MYLK2, MYLK, MCL1 MAPK9 1787/4885MAP4K4 1286/4885CSNK1D 1643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.